{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:10:42Z","timestamp":1772712642176,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","award":["C49297\/ A27294"],"award-info":[{"award-number":["C49297\/ A27294"]}],"id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jclinepi.2020.06.016","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T21:41:52Z","timestamp":1592430112000},"page":"9-18","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies"],"prefix":"10.1016","volume":"127","author":[{"given":"Francesco","family":"Cottone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelie","family":"Anota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes M.","family":"Giesinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobien M.","family":"Kieffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil K.","family":"Aaronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel","family":"Van Steen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Charton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2020.06.016_bib2","series-title":"Reflection paper on the regulatory guidance for the use of heath related quality of life (HRQL) measures in the evaluation of medicinal product","year":"2005"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib3","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jval.2016.10.006","article-title":"A review of patient-reported outcome labeling in the United States (2011-2015)","volume":"20","author":"Gnanasakthy","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib4","first-page":"1155","article-title":"Food and Drug Administration requirements for approval of new anticancer drugs","volume":"69","author":"Johnson","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib5","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib6","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","article-title":"Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib8","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1158\/1078-0432.CCR-12-0653","article-title":"U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis","volume":"18","author":"Deisseroth","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib9","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","article-title":"Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab","volume":"131","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib10","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib11","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1634\/theoncologist.2008-0003","article-title":"Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer","volume":"13","author":"Kabbinavar","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib12","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1002\/cam4.2311","volume":"8","author":"Charton","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamaoncol.2017.5082","article-title":"Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial","volume":"4","author":"Taphoorn","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1200\/JCO.2017.77.2293","article-title":"Patient-reported symptoms and impact of treatment with Osimertinib versus chemotherapy in advanced non-small-cell lung cancer: the AURA3 trial","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S1470-2045(17)30911-7","article-title":"Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial","volume":"19","author":"Chi","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s11136-019-02367-7","article-title":"Time to deterioration in cancer randomized clinical trials for patient-reported outcomes data: a systematic review","volume":"29","author":"Charton","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib17","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1016\/j.ejca.2013.07.144","article-title":"Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy","volume":"49","author":"Harland","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib18","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(16)30125-5","article-title":"Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial","volume":"17","author":"Cella","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib19","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00277-018-3469-4","article-title":"Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study","volume":"97","author":"Cella","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/10428194.2019.1666381","article-title":"Quality of life in patients with relapsed\/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population","volume":"61","author":"Ludwig","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib22","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non-small cell lung cancer: results from the CheckMate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib23","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejca.2018.05.005","article-title":"Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057","volume":"102","author":"Reck","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib24","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.31323","article-title":"Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib","volume":"124","author":"Efficace","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib25","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S1470-2045(19)30493-0","article-title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","volume":"20","author":"Laetsch","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib26","first-page":"37","article-title":"Time to quality of life improvement as a method for longitudinal analysis of treatment efficacy","volume":"26","author":"Cottone","year":"2017","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib27","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib28","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1475-6773.2005.0k375.x","article-title":"Commentary--goodbye M(C)ID! Hello MID, where do you come from?","volume":"40","author":"Schunemann","year":"2005","journal-title":"Health Serv Res"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib31","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A Class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"The Ann Stat"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib33","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/sim.2712","article-title":"Tutorial in biostatistics: competing risks and multi-state models","volume":"26","author":"Putter","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib35","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.3324\/haematol.2016.144949","article-title":"Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients","volume":"101","author":"Castagnetti","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib36","series-title":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials","year":"2017"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/EDE.0000000000000565","article-title":"Bias due to confounders for the exposure-competing risk relationship","volume":"28","author":"Lesko","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/pst.290","article-title":"Estimation of the marginal survival time in the presence of dependent competing risks using inverse probability of censoring weighted (IPCW) methods","volume":"7","author":"Matsuyama","year":"2008","journal-title":"Pharm Stat"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12955-014-0192-2","article-title":"Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study","volume":"12","author":"Anota","year":"2014","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib40","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2018.09.005","article-title":"Interpreting European Organisation for research and treatment for cancer quality of life questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma","volume":"104","author":"Musoro","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib41","first-page":"1753","article-title":"Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials","volume":"19","author":"Maringwa","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","article-title":"What changes in health-related quality of life matter to multiple myeloma patients? A prospective study","volume":"84","author":"Kvam","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib43","doi-asserted-by":"crossref","first-page":"pkz037","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced Breast cancer","volume":"3","author":"Musoro","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jclinepi.2020.06.016_bib44","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1183\/13993003.01695-2015","article-title":"Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy","volume":"48","author":"Fiteni","year":"2016","journal-title":"Eur Respir J"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435619310376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435619310376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T05:17:30Z","timestamp":1760246250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435619310376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":43,"alternative-id":["S0895435619310376"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2020.06.016","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2020.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}